Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib

Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib

Abstract Despite the benefit with cancer immunotherapies in clinical implication, immunotherapeutic resistance occurred in many patients and the mechanism remains unknown. Increasing evidence has revealed that cell‐intrinsic programmed cell death ligand 1 (PD‐L1) may play a non‐negotiable part in im...

Full description

Bibliographic Details
Main Authors: Yuan Gao, Yingfang Feng, Shaochuan Liu, Yan Zhang, Jing Wang, Tingting Qin, Peng Chen, Kai Li
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:Cancer Medicine
Subjects:
anlotinib
drug resistance
melanoma
PD‐L1
PI3K/AKT
VECs
Online Access:https://doi.org/10.1002/cam4.6195

Internet

https://doi.org/10.1002/cam4.6195

Similar Items